A Study to Evaluate Efficacy and Safety of Macitentan 75 mg in Inoperable or Persistent/Recurrent Chronic Thromboembolic Pulmonary Hypertension

Status

Active

DZG

DZL

Start date

07/07/2020

Parameters

Inclusion criteria
  • persitstent/recurrent CTEPH
Exclusion criteria
  • operable CTEPH